21,115 Shares in Repligen Corporation $RGEN Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 21,115 shares of the biotechnology company’s stock, valued at approximately $4,059,000.

Several other institutional investors have also modified their holdings of RGEN. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen in the second quarter valued at $380,756,000. Wasatch Advisors LP grew its stake in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after purchasing an additional 346,720 shares in the last quarter. Congress Asset Management Co. grew its stake in Repligen by 0.9% during the 3rd quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock worth $196,249,000 after purchasing an additional 8,681 shares in the last quarter. ABS Investment Management LLC purchased a new stake in Repligen during the 2nd quarter worth about $191,016,000. Finally, Maverick Capital Ltd. purchased a new stake in Repligen during the 1st quarter worth about $178,946,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RGEN. Zacks Research cut Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Royal Bank Of Canada raised their target price on shares of Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Barclays lifted their price target on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings cut shares of Repligen from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 2nd. Finally, Wells Fargo & Company increased their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $178.57.

Repligen Trading Down 0.8%

NASDAQ:RGEN opened at $172.62 on Thursday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $198.87. The stock has a market cap of $11.03 billion, a P/E ratio of 85.28, a P/E/G ratio of 2.98 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.43 and a current ratio of 9.88. The stock has a 50-day simple moving average of $177.31 and a 200-day simple moving average of $145.63.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.07. The business had revenue of $209.31 million for the quarter, compared to analyst estimates of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the company earned $0.46 EPS. As a group, analysts anticipate that Repligen Corporation will post 2.07 earnings per share for the current fiscal year.

About Repligen

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.